OGT and QIAGEN announce partnership that unlocks a complete sample to report workflow for SureSeq NGS panels
OGT brings clinical genomics experience to develop leading hybridization-based NGS technology delivering the insights clinical research laboratories need, every time
25 Sept 2025Industry news
The partnership between OGT and QIAGEN Digital Insights (QDI) expands OGT’s bioinformatics capabilities by integrating QIAGEN’s advanced tertiary analysis solution, QCI Interpret, with its SureSeq™ NGS panels. Purpose-built for variant interpretation and clinical reporting, QCI Interpret delivers AI-powered, expert-curated classifications along with oncologist-reviewed summaries and transparent evidence links. Through this collaboration, SureSeq™ NGS panel users gain access to streamlined, high-confidence genomic insights and efficient, scalable reporting from sample to result.
QDI has built the world’s largest expert-curated knowledge base of genomic and bioinformatic content, serving as the foundation of QCI Interpret. By combining the clinical precision of expert curation with the speed and scalability of AI-powered automation, QCI Interpret enables labs to deliver high-confidence variant interpretation and reporting. QCI Interpret empowers SureSeq customers with transparent variant classifications, oncologist-reviewed summaries, and on-demand interpretations — streamlining the path from sequencing to final report.
OGT’s suite of SureSeq NGS products has been developed with superior hybridisation-based detection capabilities to ensure clinical research labs effortlessly achieve comprehensive genomic profiling of their samples and minimize the risk of missing variants. Combined with the unmatched accuracy and consistency of QIAGEN’s proprietary software, labs gain access to an end-to-end workflow for faster, better-informed and more confident insights.
Gareth Thomson, Executive Vice President of Commercial Operations at OGT, commented, “We are delighted to be partnering with QIAGEN Digital Insights to allow OGT’s customers to package their SureSeq NGS panels with QIAGEN Digital Insights tertiary analysis software creating an end-to-end NGS workflow with access to the world’s largest knowledge base increasing customers confidence in variant classification. This partnership is an important demonstration of OGT’s commitment to providing the most relevant and impactful oncology insights”.
Nitin Sood, Senior Vice President and head of Life Sciences at QIAGEN, said, “This collaboration reinforces QIAGEN Digital Insights’ global leadership in variant interpretation to deliver scalable, collaborative and cutting-edge solutions for precision medicine. As labs face mounting challenges with the complexity and volume of NGS testing, QDI is uniquely positioned to support SureSeq workflows with transparent variant classifications, oncologist-reviewed insights and flexible reporting. This helps customers to scale confidently, reduce turnaround times, and improve outcomes for patients.”